Evidence map›Paper›PMID 40452043›Full record

ArticleDiabetology & metabolic syndrome2025

Brazilian expert consensus on the diagnosis, classification, screening for complications and treatment of familial partial lipodystrophy.

Cynthia Melissa Valerio, Luiz F Viola, Natália Rossin Guidorizzi, Josivan Gomes Lima, Amélio F Godoy-Matos, Alexandre Hohl, Fabio R Trujilho, Joana R Dantas, Julliane Tamara Araújo de Melo Campos, Lenita Zajdenverg and 5 more

Abstract read
In one paragraph

Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Cynthia Melissa ValerioBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Luiz F ViolaBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil. viola.luizfc@gmail.com.
Natália Rossin GuidorizziBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Josivan Gomes LimaBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Amélio F Godoy-MatosBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Alexandre HohlBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Fabio R TrujilhoBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Joana R DantasBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Julliane Tamara Araújo de Melo CamposBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Lenita ZajdenvergBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Raquel Beatriz Gonçalves MunizBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Rodrigo Oliveira MoreiraFaculdade de Medicina de Valença, Centro Universitário de Valença, Valença, RJ, Brazil.
Virgínia Oliveira FernandesBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Maria Cristina Foss-FreitasBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.
Renan MontenegroBrazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPartial lipodystrophies are a rare and heterogeneous group of diseases characterized by variable loss of adipose tissue. Around the world, the high heterogeneity in phenotypic expression, limited awareness, and absence of standardized diagnostic criteria for familial partial lipodystrophies (FPLD) may contribute to the underdiagnosis of genetic forms. The estimated high prevalence of FPLD in Brazil, combined with resource limitations in the healthcare system and a lack of specialized medical centers, presents significant challenges in the diagnosis and treatment of lipodystrophy-related conditions. This expert consensus aimed to establish clinical criteria for FPLD suspicion and diagnosis, propose a flowchart for clinical and complementary evaluation, and provide a framework for managing FPLD-related disorders and complications.

methodsA consensus was reached following discussions with 15 experts from Brazilian lipodystrophy referral centers specializing in the diagnosis and management of partial lipodystrophies. Using a combination of face-to-face meetings and online and offline activities, the panel addressed five key aspects of FPLD management: clinical suspicion and diagnosis of the condition, classification of the most common subtypes, multisystem manifestations, screening for complications, and therapeutic approaches.

resultsTwo clinical criteria were proposed for the suspicion of FPLD: one mandatory criterion, characterized by lipoatrophy in the lower limbs, and at least one of the following conditions associated with FPLD: hypertriglyceridemia and/or low high-density lipoprotein cholesterol, diabetes mellitus, impaired fasting glucose or glucose intolerance, metabolic-associated steatosis liver disease, early coronary atherosclerotic disease, acanthosis nigricans, and polycystic ovary syndrome. To confirm the diagnosis, different combinations of criteria were suggested: presence of the mandatory criterion along with either two major criteria, one major and two minor criteria, or a positive genetic test with a mandatory criterion.

conclusionsThis expert consensus provides a feasible guide based on signs of lipoatrophy and metabolic abnormalities observed in Brazilian centers of lipodystrophy to enhance clinical suspicion and enable early diagnosis of FPLD. Through adequate screening for FPLD-related complications, a therapeutic approach has been proposed that includes lifestyle modifications, early interventions for comorbidities, and targeted pharmacological treatment.

Indexed as

DiagnosisGeneticsHypertriglyceridemiaInsulin resistanceLipodystrophyPancreatitisTherapy

Identifiers

PMID40452043
PMCPMC12128538

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.